Ovarian Cancer

BARCELONA, Spain — The addition of olaparib to bevacizumab maintenance therapy after first-line platinum-based chemotherapy and bevacizumab significantly improved PFS among women with advanced ovarian cancer, according to results of the randomized phase 3 PAOLA-1/ENGOT-ov25 study presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — Niraparib significantly extended PFS among women with newly diagnosed advanced ovarian cancer, according to results of the randomized phase 3 PRIMA study presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — The combination of cediranib and olaparib appeared to be effective and safe for women with heavily pretreated, platinum-resistant ovarian cancer, according to results of a randomized phase 2 study presented at European Society for Medical Oncology Congress.

Among the top stories in hematology/oncology last week were the USPSTF recommending that clinicians offer preventive medications to asymptomatic women at elevated risk for breast cancer, and a study that suggested symptoms of PTSD may be associated with increased risk for ovarian cancer.

Symptoms of PTSD appeared associated with increased risk for ovarian cancer, especially among premenopausal women, according to study results published in Cancer Research.

September is Gynecologic Cancer Awareness Month, an awareness campaign launched by the Foundation for Women’s Cancer.

Click here to read the Cover Story, “AI an emerging tool, not substitute, for oncologists.”

There will be 22,530 new cases of ovarian cancer in the United States this year.

Breast, colorectal and ovarian cancers are among the most common cancers that affect women, according to the American Cancer Society. The mortality rates associated with these cancers in women vary drastically. This year, there will be an estimated 41,760 deaths attributed to breast cancer, 23,240 deaths attributed to colorectal cancer, and 13,980 deaths attributed to ovarian cancer in the United States.

The introduction of poly (ADP-ribose) polymerase, or PARP, inhibitors has made a significant impact in ovarian cancer, prolonging PFS among certain patients, particularly those with BRCA mutations.